439 reports of this reaction
2.0% of all ATROPINE SULFATE reports
#11 most reported adverse reaction
BRADYCARDIA is the #11 most commonly reported adverse reaction for ATROPINE SULFATE, manufactured by Apotex Corp.. There are 439 FDA adverse event reports linking ATROPINE SULFATE to BRADYCARDIA. This represents approximately 2.0% of all 21,488 adverse event reports for this drug.
Patients taking ATROPINE SULFATE who experience bradycardia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
BRADYCARDIA is a less commonly reported adverse event for ATROPINE SULFATE, but still significant enough to appear in the safety profile.
In addition to bradycardia, the following adverse reactions have been reported for ATROPINE SULFATE:
The following drugs have also been linked to bradycardia in FDA adverse event reports:
BRADYCARDIA has been reported as an adverse event in 439 FDA reports for ATROPINE SULFATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
BRADYCARDIA accounts for approximately 2.0% of all adverse event reports for ATROPINE SULFATE, making it a notable side effect.
If you experience bradycardia while taking ATROPINE SULFATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.